Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply

Affiliations

¹ Center for Drug Evaluation and Research, Office of New Drugs, Office of Oncologic Diseases, Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: jennifer.gao@fda.hhs.gov.
² Office of Translational Sciences, Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
³ Center for Drug Evaluation and Research, Office of New Drugs, Office of Oncologic Diseases, Food and Drug Administration, Silver Spring, MD 20993, USA.

Comment

Jennifer J Gao et al. Lancet Oncol. 2020 Mar.

. 2020 Mar;21(3):e131.

doi: 10.1016/S1470-2045(20)30095-4.

¹ Center for Drug Evaluation and Research, Office of New Drugs, Office of Oncologic Diseases, Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: jennifer.gao@fda.hhs.gov.
² Office of Translational Sciences, Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
³ Center for Drug Evaluation and Research, Office of New Drugs, Office of Oncologic Diseases, Food and Drug Administration, Silver Spring, MD 20993, USA.

No abstract available

Comment on

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM. Gao JJ, et al. Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859246
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
Pala L, Conforti F, Goldhirsch A. Pala L, et al. Lancet Oncol. 2020 Mar;21(3):e130. doi: 10.1016/S1470-2045(20)30072-3. Lancet Oncol. 2020. PMID: 32135114 No abstract available.